Podcasts about Thyroid cancer

Stephanie Thaler has lived many lives in one. She survived thyroid cancer at 18, gained 60 pounds during radiation treatment while being isolated in a hospital with zero human contact, and came out the other side with a calling — massage therapy. What followed was 28 years of relentless learning, Guinness World Record-breaking fitness (715 burpees in 60 minutes), becoming the massage therapist for the Minnesota Vikings and the 2022 US Women's Olympic Hockey Team, founding the first barefoot massage school in Minnesota, and becoming the highest-paid manual therapist in her state through a technique called adhesion release methods — a specialized approach to releasing nerve entrapments that only 50 practitioners worldwide are certified in. In this conversation with Freddie, Stephanie breaks down what adhesions actually are, why nerve entrapment goes undetected on MRIs and gets dismissed by conventional medicine, how she's getting results in four to six sessions for people who have been in chronic pain for years, and what the difference is between radial and focused shockwave therapy when treating specific nerve pathways. The second half of this episode goes somewhere deeply personal. Stephanie shares that her father died by suicide on Thanksgiving when she was five years old — and that she spent the next 38 years living in a state of chronic fight or flight, cycling through every SSRI, CBT protocol, and alternative therapy available, never finding lasting relief. Until ketamine. In two weeks of six IV sessions, she healed more trauma than 18 years of cognitive behavioral therapy ever touched. Her father came to her in session. God held her. And she came out glowing. She now does at-home ketamine therapy three to five days a week and credits it with putting her depression into remission and fueling the most successful chapter of her career. This is an honest, science-grounded, spiritually rich conversation about healing the body and the nervous system from the inside out — and what becomes possible when you finally feel safe. Highlighted Moments  [00:00] Understanding Collagen and Nerve Entrapment  [01:56] The Science Behind Red Light Therapy  [03:21] Supporting Immune Function with SilverBiotics  [04:13] Personal Journey: From Cancer to Fitness  [05:27] Training for a World Record in Burpees  [06:49] The Impact of Cancer on Body and Mind  [10:26] Tissue Mechanics and Emotional Trauma  [13:17] Evolving Techniques in Bodywork and Therapy  [16:25] Releasing Nerve Adhesions for Pain Relief  [18:12] Chronic Nerve Entrapment and Treatment Duration  [19:24] Cost and Value of Advanced Therapy Sessions  [21:30] Practitioner Longevity and Body Care  [23:01] Working with High-End Athletes  [25:32] Biohacking Tools and Self-Care Routines  [31:35] Focused Shockwave and Brand Technologies  [35:17] Home Biohacking and Contrast Therapy  [37:36] Future Vision: Wellness Barns and Community Spaces  [41:33] Advice for Aspiring Practitioners  [46:57] Being Beautifully Broken: Embracing Imperfection  [48:00] Ketamine and Mental Health Transformation  [50:54] The Power of Neural Rewiring and Support  [53:31] The Role of Set and Setting in Therapy  [56:27] Research and Future of Medical Psychedelics  [57:17] Where to Find Stephanie and Resources Connect with Stephanie: https://stephaniethalerlmt.com Upgrade Your Health LightPathLED: https://lightpathled.pxf.io/c/3438432/2059835/25794 Code: beautifullybroken Silver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD 30% off with Code: BEAUTIFULLYBROKEN Bimini: https://biminihydrotherapy.com/?rfsn=8883833.3df4c7 Code: beautifullyborken CONNECT WITH FREDDIEWork with Me: https://www.beautifullybroken.world/biological-blueprintWebsite and Store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/freddie.kimmelYouTube: https://www.youtube.com/@beautifullybrokenworld Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In Top of the News Stack, Greg Belfrage goes over the latest headlines including the results of the Republican Primary Runoff in Texas, Florida redistricting their maps, Trump's annual medical exam, Joe Biden sues the DOJ, Pam Bondi diagnosed with thyroid cancer, and more...See omnystudio.com/listener for privacy information.

What are the experts saying about thyroid cancer treatment in 2025?  Maybe it's time to discuss deescalation of aggressive surgical care for lower risk thyroid cancers.  We can accept that less surgery may be appropriate in select cases, including more thyroid lobectomies versus total thyroidectomies, consider less invasive approaches such as percutaneous ablation techniques, and utilize more observation with active surveillance.  Early assessment of treatment may allow appropriate reduction in use of radioactive iodine ablation and more relaxed routine monitoring can reduce surveillance burden to patients and providers. Hosts:  - Amanda Doubleday, DO, MBA, Assistant Professor, Waukesha Surgical Specialists, ProHealth Care.  Affiliated with University of Wisconsin School of Medicine and Public Health, Department of Surgery.  - Simon Holoubek, DO, MPH, Assistant Professor, University of Wisconsin School of Medicine and Public Health, Department of Surgery.  - Alexander Chiu, MD, Assistant Professor, University of Wisconsin School of Medicine and Public Health, Department of Surgery.  - Rebecca S Sippel, MD, FACS, Professor and Chair of Division of Endocrine Surgery, Vice Chair of Academic Affairs and Professional Development, University of Wisconsin School of Medicine and Public Health, Department of Surgery.  Learning Objectives:- Risk stratification system now includes 4 categories: low, low-intermediate, high-intermediate, and high-TSH suppression targets are simplified:  below the normal range if there is structural or biochemical disease and in the normal range if disease free. - Thyroid lobectomy is recommended for tumors < 2cm cT1N0 tumors and can be considered for tumors 2-4 cm. - Micro-Papillary Thyroid Carcinoma (

Send us Fan MailMorning Prayer (Word; PR356; Fear The LORD; Phil 4.4,6,7,8,9; Thyroid Cancer; 1st Resp)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

In this episode of A Tale of Two Hygienists, Jessica and David sit down with dental hygienist Angeli Walton to share her powerful story of recognizing early signs of a thyroid condition—within herself. What began as clinical awareness quickly turned into a deeply personal journey, as Angeli navigated the unexpected shift from provider to patient.   Angeli reflects on how her training helped her notice subtle changes that might have otherwise gone overlooked, and how trusting those instincts ultimately led to early detection. The conversation explores the emotional and professional impact of experiencing healthcare from the other side of the chair, offering a unique perspective that many clinicians don't anticipate, but can learn from.   Together, they discuss the broader role dental professionals play in identifying systemic health concerns, and why paying attention to small details can make a life-changing difference. Angeli also shares insights on self-advocacy and why it's critical for clinicians to speak up—both for their patients and themselves.   This episode offers a meaningful reminder that the skills used every day in practice extend far beyond oral health, and can be just as important in protecting your own well-being.   What We Talked About:   Recognizing early signs of systemic conditions How clinical instincts can support early detection The experience of transitioning from provider to patient Why subtle symptoms shouldn't be ignored The importance of self-advocacy in healthcare   If you found this episode valuable, be sure to subscribe to A Tale of Two Hygienists, leave a review, and share it with colleagues who are passionate about whole-body health and early detection.   Resources:   Email: Angeli.damron@gmail.com Instagram: @angeliwalton

In this episode of A Tale of Two Hygienists, Jessica and David sit down with dental hygienist Angeli Walton to share her powerful story of recognizing early signs of a thyroid condition—within herself. What began as clinical awareness quickly turned into a deeply personal journey, as Angeli navigated the unexpected shift from provider to patient.   Angeli reflects on how her training helped her notice subtle changes that might have otherwise gone overlooked, and how trusting those instincts ultimately led to early detection. The conversation explores the emotional and professional impact of experiencing healthcare from the other side of the chair, offering a unique perspective that many clinicians don't anticipate, but can learn from.   Together, they discuss the broader role dental professionals play in identifying systemic health concerns, and why paying attention to small details can make a life-changing difference. Angeli also shares insights on self-advocacy and why it's critical for clinicians to speak up—both for their patients and themselves.   This episode offers a meaningful reminder that the skills used every day in practice extend far beyond oral health, and can be just as important in protecting your own well-being.   What We Talked About:   Recognizing early signs of systemic conditions How clinical instincts can support early detection The experience of transitioning from provider to patient Why subtle symptoms shouldn't be ignored The importance of self-advocacy in healthcare   If you found this episode valuable, be sure to subscribe to A Tale of Two Hygienists, leave a review, and share it with colleagues who are passionate about whole-body health and early detection.   Resources:   Email: Angeli.damron@gmail.com Instagram: @angeliwalton

In this episode of Better Edge, Northwestern Medicine Endocrinologist Ioannis Papagiannis, MD, reviews key updates from the 2025 American Thyroid Association Differentiated Thyroid Cancer Guidelines. He highlights refined, pathology specific risk stratification and a growing emphasis on individualized care. The discussion explores treatment de-escalation strategies, including active surveillance, surgical decision making, selective radioactive iodine use and tailored follow up, all designed to improve outcomes while minimizing overtreatment.

Dr. Nabil Saba shares the first evidence-based guideline on thyroid cancer from ASCO. He highlights recommendations on first- and subsequent-line systemic treatment – including multikinase inhibitors (MKIs), genomically targeted therapies, immunotherapy, and cytotoxic chemotherapy across four subtypes of thyroid cancer: well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. He dives into the evidence supporting each recommendation and explains the importance of shared decision-making on the risks and benefits of each treatment option. Dr. Saba also touches on outstanding questions including sequencing of agents, addressing resistance, emerging biomarker targets, and management of toxicities. Read the full guideline, "Systemic Treatment of Thyroid Cancer: ASCO Guideline." TRANSCRIPT This guideline, clinical tools and resources are available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology. Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Nabil Saba from Emory University, lead author on "Systemic Treatment of Thyroid Cancer: ASCO Guideline." Thank you for being here today, Dr. Saba. Dr. Nabil Saba: Pleasure to be here. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Saba, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we're here today to talk about, Dr. Saba, could you start us off by providing a general overview of the scope and purpose of this first ASCO guideline for thyroid cancer? Dr. Nabil Saba: So thyroid cancer is a complex disease, and the complexity has been added with the advent of multiple systemic therapeutic agents that have recently come on as part of the standard of care for treating this disease. The guidelines have lagged behind, I believe, in terms of being able to clearly delineate how to use these agents and what clinical settings to use them. And so this guideline, I think, is a much-needed and much-awaited guideline for clinicians to allow them to understand better the use of systemic agents in the treatment of thyroid cancer. And when we talk about systemic agents, what we want to specify is this applies mostly for patients with recurrent metastatic disease, patients who have failed the standard initial treatment, which continues to be surgical resection for these patients if surgery is possible, in addition to radioiodine therapy for the right clinical setting. Brittany Harvey: Absolutely. It's a good point that this patient population for this guideline focuses mainly on recurrent disease and patients who have already received surgery and radioactive iodine therapy. So then this guideline covers four subtypes of thyroid cancer, including well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. As you mentioned, you address clinical questions on systemic therapies, including multikinase inhibitors, genomically targeted therapies, immunotherapy, and cytotoxic chemotherapy in both the first-line and subsequent lines for each of these subtypes. So I'd like to review the key recommendations by subtype. So first, what are the key points for systemic therapy for well-differentiated thyroid cancer? Dr. Nabil Saba: It's important to also stress the point that we have these different subtypes of thyroid cancer. So when we talk about radioiodine refractory, those are for patients who are candidates for radioiodine therapy, of course. This usually encompasses the well-differentiated thyroid cancer. So for this group of patients, the guideline focuses on whether the use of multikinase inhibitors compared to placebo or observation impacts the survival in the first-line setting, whether the use of targeted therapies compared to placebo impacts also the survival in the first-line setting, all in the radioiodine refractory setting, of course. And then we tackle the issue of immunotherapy because this also is a topic that has entered the realm, if you like, of thyroid cancer and is being used in some subtypes of thyroid cancer. So we thought it would be important to raise the question of the role of immunotherapy compared to targeted agents or multikinase inhibitors, in addition to the role of cytotoxic therapy or chemotherapy, as we say, in this patient population. So the guideline goes through all of these questions and then makes specific recommendations as to the use of some of the agents in the first-line setting and second-line setting in case these patients progress after first-line setting. So, for example, it's clear that for patients who are radioiodine refractory and who have well-differentiated thyroid cancer, multikinase inhibitors are centerpiece of the first-line treatment option. And for this patient population, the recommendation essentially is to use lenvatinib or sorafenib, even though lenvatinib is considered to be the first choice in this patient population in the first-line setting. For the subsequent line settings, patients should be offered cabozantinib, which has been also proven in randomized trials. As far as genomically targeted therapy, there is always the contention of whether these agents should be initiated first in case the patient has a genomically altered disease. And so, for example, if the patient has a RET alteration or NTRK alteration, the recommendation here is in favor of using RET-targeted therapies such as selpercatinib or NTRK-targeted therapies such as larotrectinib or entrectinib for these patients as a first-line setting. If they do have the BRAF alteration, which is a commonly seen alteration in these settings, the guideline essentially indicates that this may be offered initially prior to treatment with multikinase inhibitors as well, even though the quality of the evidence here is rather lower, and the strength of the recommendation is conditional. And so it's clear that multikinase inhibitors, in the absence of any of these genomic alterations, is really the first line, and then the question becomes when do we use these genomically targeted approaches in patients who have genomically altered disease? Which basically introduces also the complexity of the question here because we have multiple agents depending on these genomic findings. And then it is sometimes confusing for practitioners which one to use or what do we use first? And so I think the guideline provides clarity in terms of what is acceptable, what is rather not acceptable, what is based on a strong recommendation, what is based on a rather weaker recommendation. I think that's part of the value of such a guideline. And then finally we have the question of radioiodine well-differentiated and the question of immunotherapy as a first line. And here we do not recommend using immunotherapy for this patient population. For patients with subsequent line settings, potentially adding pembrolizumab to a multikinase inhibitor is mentioned, however the evidence is low, and the strength of the recommendation is also conditional here. As far as chemotherapy, this is not recommended in this day and age for this patient population, however it may be considered also in patients who fail or progress on genomically targeted therapy and/or multikinase inhibitors. So this is the summary of the recommendations for well-differentiated thyroid cancer, but certainly, for details, I would refer you to the actual guideline since there are many nuances that cannot be covered during just this discussion. Brittany Harvey: Certainly. The full guideline will be available for listeners in our show notes, and there are many recommendation tables and figures that can help folks as they think through these recommendations. A lot of those key points are really important as clinicians think through which systemic therapies to offer and sequencing of these agents, as you mentioned. Following those recommendations for well-differentiated thyroid cancer, what are the recommendation highlights for systemic therapy for differentiated high-grade or poorly differentiated thyroid carcinoma? Dr. Nabil Saba: This entity is rather a rare entity. It's important to stress the fact that this entity has not really been very well represented in clinical trials, and so when we talk about differentiated high-grade or poorly differentiated, the information here is limited. However, the guideline infers on the recommendations to this subtype of thyroid cancer based on what we know for other subtypes. And I think because of the strength of evidence we have in the well-differentiated and the anaplastic thyroid cancer, this guideline for this subgroup of patients draws from these two guidelines and sort of makes recommendations based on this. So in the first-line setting, of course, if patients don't have a genomically altered disease, we certainly would recommend lenvatinib or sorafenib like we do in the well-differentiated disease. For patients with genomically altered diseases, we follow sort of the same guideline as we have followed for the well-differentiated setting, with the caveat that the quality is rather lower here and the strength of the recommendation is rather conditional for this subtype of patients. And so I think the take-home message is we do have these recommendations similar to the well-differentiated, but the strength of these recommendations for this particular subgroup of thyroid cancer patients is not as strong, given the under-representation in clinical trials. And that's basically the summary of this disease. Same applies to immunotherapy as well as chemotherapy here. Brittany Harvey: Absolutely. I think it's important to recognize where the evidence is not as strong, it's really important that the guideline panel has still offered up some recommendations to help clinicians in their daily practice as well. The next subtype the guideline panel addressed, what does the expert panel recommend regarding systemic therapy for anaplastic thyroid cancer? Dr. Nabil Saba: So it's important to remind the audience that this is a disease with dismal outcome, and this is rather a very, very rare type of thyroid cancer. So the challenge with anaplastic is we've had very little traditionally in terms of options for patients. However, this guideline highlights the advances that have happened in this disease over a relatively short period of time and stresses the important role of systemic agents. And so, for example, for non-genomically mutant anaplastic thyroid cancer in the first-line setting, the guideline does recommend lenvatinib with or without pembrolizumab. Even though the evidence of the quality is low and the strength of the recommendation is conditional, there is enough data that this recommendation could be made. The added complexity for anaplastic thyroid cancer is that this is a disease where multimodal approaches initially are really encouraged as well, including surgical resection primarily, but also potentially thinking about other modalities such as radiation therapy, as these patients have usually very aggressive disease. And so as far as genomically targeted approaches, the story of targeting BRAF I believe has been a successful story in this disease. And again, for patients with BRAF V600E mutated anaplastic thyroid cancer in the first-line setting, the guideline is clear in saying that we should offer BRAF/MEK inhibitor targeted therapy, namely dabrafenib and trametinib based on published data; the quality is moderate, though the strength of the recommendation is strong, essentially because of the compelling data in these rather small studies. In the first-line setting, again, we may offer also BRAF/MEK inhibition with or without pembrolizumab as well, and the strength here is low, with the recommendation being conditional as well. So you can see here that unlike the other types, immunotherapy may play a bigger role here in this type of cancer compared to the well-differentiated carcinoma because of the nature of the disease, and this has been also stressed in other guidelines. For patients who progress on genomically targeted therapy, there are not too many options, even though people can revert back to lenvatinib or lenvatinib and pembro. We do recommend participation in clinical trials for these patients because we really don't have any clear-cut options since the strength of these recommendations is conditional for these patients. As far as the question of immunotherapy per se, we talked about lenvatinib with pembrolizumab. There is also data on ipilimumab and nivolumab. So we include that also as an option for the first-line setting, and we also include, obviously, the dabrafenib and trametinib in combination with pembrolizumab. And even though all these recommendations are conditional, the size of these clinical trials are single-arm phase II studies. In terms of chemotherapy, again, no recommendation in the first-line setting. However, for patients who fail MKI or fail immunotherapy, clinicians may offer cytotoxic chemotherapy. So you can see that in this rare disease, the recommendations already in 2026 indicate a complex tree of decision-making for a number of these cases. And I think this is where these guidelines offer value to many of the practitioners out there. Certainly, they don't claim to answer any or every possible clinical scenario for these patients because anaplastic thyroid cancer, like any thyroid cancer or any malignancy, usually has to rely on careful evaluation on a case-by-case basis, and for this disease in particular, on a multidisciplinary evaluation based on evaluation by surgical team, by medical oncology, by radiation oncology. But hopefully, these guidelines help at least put in the systemic therapy within that context. Brittany Harvey: Absolutely. I think this is also where, in the guideline, the clinical interpretation can really be helpful for readers. And as you mentioned, that multidisciplinary collaboration along with shared decision-making with patients on the risks and benefits of each treatment option is really critical here. So the final subtype that the guideline expert panel addressed, what systemic therapies are recommended for medullary thyroid cancer? Dr. Nabil Saba: Yes, so medullary thyroid cancer is a separate disease in its own merit, and biologically it's different from the other diseases. And even though it's a relatively rare thyroid cancer, there has been quite substantial advances in systemic therapy, and I think the guideline importantly highlights these advances for this type of thyroid cancer, and this subtype adds to the value of the guideline as well. For these cancers, targeted therapy for patients who have RET alteration is really recommended as a first line. So for patients who have RET mutant disease, selpercatinib certainly is the treatment of choice, and this is based on high evidence and the recommendation being very strong here because it's based on randomized phase III data. In the subsequent line settings, however, patients with RET-altered disease who have progressed on selpercatinib, unfortunately, we don't have clear-cut recommendations, however, participation in clinical trials is recommended. If a trial is not available, we recommend that patients be offered vandetanib or cabozantinib in this situation. For patients without the RET alteration, in other words, for patient populations with wild-type disease, the first-line setting should include cabozantinib or vandetanib based also on improved progression-free survival in randomized clinical trial, and here the recommendation is quite strong. In terms of the role of immunotherapy here, there is very, very little role, and so we don't recommend using immunotherapy in the first-line setting or subsequent line setting. Similarly, for chemotherapy or cytotoxic chemotherapy, it's not recommended that patients be exposed to cytotoxic chemotherapy outside of a clinical trial, whether this be in the first-line setting or second-line setting. We say that in the second-line setting, if patients have failed genomically targeted therapy, clinicians may offer cytotoxic therapy, however, here the evidence is low, and the strength of the recommendation is conditional. And so clearly that tells you that advances have been substantial in this disease, specifically in the realm of targeted therapies, which is importantly highlighted in this guideline as well. Brittany Harvey: Yes, it's great to see the advances across these different subtypes. So thank you for reviewing all of these recommendations. It's clear you and the panel spent a lot of time reviewing the evidence to craft these recommendations. So you've already touched on this throughout our conversation already, but I'd like to ask, in your view, Dr. Saba, what is the importance of this guideline, and how will it impact both clinicians and patients with thyroid cancer? Dr. Nabil Saba: This is a guideline that's important because of the complexity of management of thyroid cancer, in addition to the fact that there has been quite a few systemic therapeutic agents that have come to the scene in the disease, and those are used in specific situations. We talked about medullary thyroid cancer and the story of RET inhibition, for example, the question of sequencing of these agents is important - what do you choose first in terms of your choice depending on the clinical scenario, I think, is highlighted in this guideline. I think this is going to be extremely helpful to practitioners inside and outside the United States because it is going to offer a guide for them to essentially decide on what would be the standard therapeutic option that should be offered to these patients. I know that many of these agents are not perhaps available in other countries, and I hope this guideline will also raise awareness, since it is coming from ASCO, that these agents need to be explored and considered for a large group of the population that may not have access to them, especially outside the United States and in third-world countries. And so I think from that angle, I think also the guideline is important in that it sets what is the accepted standard in terms of systemic therapy for these patients with these different diseases. Brittany Harvey: Yes, these evidence-based guidelines certainly set a standard and it will be really important to have these in the hands of many different people to inform best practices for care. Additionally, you've also mentioned earlier that several of the recommendations referred patients to clinical trials where there wasn't evidence. So I'd like to ask, what are the outstanding questions and ongoing research you are watching in the thyroid cancer space? Dr. Nabil Saba: This guideline I would like to look at it as a start. This is a much-needed start, however, it also exposes us to the fact that there are so many unanswered questions yet. We still don't know the exact way or best way to sequence these agents. The story of, for example, multikinase inhibitors in well-differentiated thyroid cancers that have BRAF alteration, what is to be started first? Do you start with a multikinase inhibitor, or do you start with a BRAF inhibition? This is a topic of a cooperative group trial currently answering these questions in terms of what is the best sequencing because, you know, you do have the approved cabozantinib in the second line, for example, but you also have the approved BRAF inhibition, which could be done in the first or second line. And so sometimes that is confusing to clinicians for a good reason because no studies have really examined the question of the appropriate sequencing of these agents. And so I think the more we get these agents as available options for treating patients, the more pressing the question would be of what would be the best sequencing. So I think that's a major question to tackle, and hopefully clinical trials will tackle that. I think the question of resistance to some of these agents, we don't talk too much about that in the guideline, but certainly these agents have limitations. Not every patient who gets a genomically targeted approach is to benefit from that. We've seen many patients who progress on these, and so the question is, how to overcome resistance? Even for the strong data that we have, for example, on RET alteration or NTRK, resistance mechanisms do happen, and we've seen patients who fail larotrectinib and then they need to go on other therapeutic options. And so I think clinical trials are crucial in answering all these questions, in addition to targeting other subtypes of thyroid cancers that have not really been very common. We know that RAS is also seen in some thyroid cancers, HRAS. There have been some studies along that line. ROS is another potential target. And so the question of resistance, I think the question of sequencing, in addition to the question of toxicity. Because, you know, how best to dose these agents? We talked about this a little in the guideline, but again, the focus on this guideline was not too much the toxicity management. So I think management of toxicities should also be a topic of interest that needs to probably accompany any systemic therapy guideline since we're using agents that people may not be too familiar with when they use it for the first time. Brittany Harvey: Definitely. We'll look forward to the results of these trials that you mentioned to inform sequencing, resistance, new targets, and addressing toxicity and potentially inform updates to this guideline. So I want to thank you so much for your work to develop this first ASCO guideline for thyroid cancer and for your time today, Dr. Saba. Dr. Nabil Saba: It's been my pleasure and it's been a pleasure to actually accomplish this and publish this guideline because I do believe it will be of great benefit to the oncologic community. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/head-neck-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

- Overview of Thyroid Cancer - Diagnosis & Staging - Updates on Treatment Options - Clinical Trial Updates - New Treatment Approaches for Refractory Thyroid Cancer - Preventing & Managing Treatment Side Effects, Symptoms, Discomfort & Pain - The Importance of Communicating with Your Health Care Team: Key Questions to Ask - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Nutrition & Hydration Concerns & Tips - Questions to Ask Your Health Care Team about Your Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Thyroid Cancer - Diagnosis & Staging - Updates on Treatment Options - Clinical Trial Updates - New Treatment Approaches for Refractory Thyroid Cancer - Preventing & Managing Treatment Side Effects, Symptoms, Discomfort & Pain - The Importance of Communicating with Your Health Care Team: Key Questions to Ask - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Nutrition & Hydration Concerns & Tips - Questions to Ask Your Health Care Team about Your Quality-of-Life Concerns - Questions for Our Panel of Experts

In this episode of SurgOnc Today®, Drs. Jason Liu and Sonya Khan will demystify the risks of thyroid cancer and the use of GLP-1s. They will also provide practical advice for surgeons by answering real questions that their patients have asked.

In this heartfelt episode of The Summits Podcast, cohosts Vince Todd, Jr. and Daniel Abdallah sit down with twin sisters Liz Childers and Norma Unser to share an inspiring and deeply personal conversation about their family's journey with cancer. Liz and Norma open up about how cancer has profoundly impacted their lives, with their mom, Liz, and Norma all facing breast cancer diagnoses. They discuss the emotional and physical challenges of their battles, the critical role of routine screenings in early detection, and the strength they've found in each other. The conversation also highlights the groundbreaking work of the Cancer Vaccine Coalition and the hope it brings for the future of cancer outcomes and prevention. Liz and Norma's story is a powerful reminder of resilience, the importance of advocacy, and the strides being made in the fight against cancer. Learn more about the Cancer Vaccine Coalition: https://cancervaccinecoalition.org/ Shop Lizzie Lu's Crew hats! https://lizzielucrew.com/

Join Liz Cruz M.D. and Tina Nunziato, Certified Holistic Nutrition Consultant, as they discuss a recent video they were introduced to regarding the rise of thyroid cancer due to frequent mammograms. Find out if the claims are true and what you can do to protect your thyroid during your next mammogram.   Mid-podcast commercial was on the Delicate Detox.  Please check out this link for more information: https://drlizcruz.com/collections/supplements/products/dr-liz-cruz-delicate-detoxWatch us on YouTube:  https://youtu.be/JqVW1YcNiUs Dr. Cruz is a Board Certified Gastroenterologist who practices in Phoenix, AZ. Along with her wife Tina Nunziato, a Certified Holistic Nutritionist, they have helped tens of thousands of individuals get well from a more holistic standpoint. They focus on issues such as constipation, diarrhea, acid reflux, heartburn, gas, bloating, food sensitivities, IBS, Crohn's disease, and diverticulitis in addition to a person's general overall health. They do this by teaching about real food, water, digestive enzymes, probiotics, detox, greens, electrolytes, food sensitivity testing, and so much more. If you're struggling with finding the answers to your issues, tired of not feeling well, and sick of taking over the counter and prescription medicines, schedule a FREE 30 minute phone consult at www.drlizcruz.com.For more information visit www.digestthispodcast.com or www.drlizcruz.com. Enjoy the show! Dr. Liz Cruz and Tina Nunziato, CHNC

This week's guest is the amazing Lorah, from Leeds. Lorah is a mother of four, who found herself pregnant with her son, Luca, during her treatment for thyroid cancer. She shares her journey of breastfeeding her four children, who all had different challenges, and the emotional rollercoaster tied to her cancer treatment and weaning. She discusses her support systems and the difficult decision to delay treatment so that she could breastfeed Luca. Lorah highlights the emotional and physical struggles, the process of treatment, and the importance of support groups and communities for those going through similar experiences.My picture book on how breastfeeding journeys end, The Story of Jessie's Milkies, is available from Amazon here -  The Story of Jessie's Milkies. In the UK, you can also buy it from The Children's Bookshop in Muswell Hill, London. Other book shops and libraries can source a copy from Ingram Spark publishing.You can also get 10% off my books on supporting breastfeeding beyond six months and supporting the transition from breastfeeding at the Jessica Kingsley press website, that's uk.jkp.com using the code MMPE10 at checkout.Follow me on Instagram  @emmapickettibclc or find out more on my website www.emmapickettbreastfeedingsupport.comResources mentioned - Macmillan Cancer Support https://www.macmillan.org.uk/Maggie's, Yorkshire https://www.maggies.org/our-centres/maggies-yorkshire/Mummy's Star https://www.mummysstar.org/Leeds Bosom Buddies https://northleeds.mumbler.co.uk/leeds-bosom-buddies-support-groups/ This podcast is presented by Emma Pickett IBCLC, and produced by Emily Crosby Media.

This new mini-series on Behind the Knife will delve into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program. This second episode highlights the thyroid cancer operative standard.Hosts:Tracy Wang, MD, MPH, FACS is a Professor of Surgery and Vice-Chair of Strategic and Professional Development at the Medical College of Wisconsin with a clinical focus on endocrine surgical oncology. Vladmir Neychev, MD, PhD is a Professor of Surgery at the University of Central Florida College of Medicine with a clinical focus on endocrine surgical oncology.Jack Sample, MD (@JackWSample) is a General Surgery Resident at Mayo Clinic Rochester.Guests:Elizabeth Grubbs, MD (@EGrubbsMD) is a Professor of Surgical Oncology at MD Anderson where she specializes in endocrine tumors, with expertise in cancer of the thyroid.David Hughes, MD is a Clinical Associate Professor of Surgery at University of Michigan, where he focuses on surgical diseases of the endocrine system, including a particular focus on the diagnosis and management of papillary thyroid cancer.Learning Objectives: Understand key preoperative and intraoperative aspects of the evaluation and treatment of patients with biopsy-proven papillary thyroid carcinoma (PTC) greater than or equal to 1 cm. Define factors that guide decision making regarding the extent of surgical resection (lobectomy versus total thyroidectomy) for PTC.Links to Papers Referenced in this EpisodeOperative Standards for Cancer Surgery, Volume 2: Thyroid, Gastric, Rectum, Esophagus, Melanomahttps://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/Kindle edition:Amazon.com: Operative Standards for Cancer Surgery: Volume 2, Section 1: Thyroid eBook : Program, American College of Surgeons Clinical Research, Katz, Matthew HG: Kindle StoreImpact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 years. https://pubmed.ncbi.nlm.nih.gov/25337927/ Extent of Surgery Affects Survival for Papillary Thyroid Cancer. https://pubmed.ncbi.nlm.nih.gov/17717441/Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content.  Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro - Health - The Medical World - and much more! 00:29:18 - Accutane - Update - Eye Pictures 00:52:05 - Blood Sugar 00:59:39 - Stage 3 Melanoma Cancer - Thyroid Cancer 01:43:30 - Anxiety and Panic attacks - Lethargic - Lack of Periods - Low Blood Pressure - Constipation 01:59:35 - Seed oils 02:03:38 - Conception  00:29:18 - Accutane - Update - Eye Pictures After a week of doing the diet and herbs, my life did a complete 180, it was the craziest experience ever! 00:52:05 - Blood Sugar I have a question about being on an all-fruit /vegetable diet. 00:59:39 - Stage 3 Melanoma Cancer - Thyroid Cancer They cut out her entire thyroid and I think the parathyroids too.  01:43:30 - Anxiety and Panic attacks - Lethargic - Lack of Periods - Low Blood Pressure - Constipation Do antidepressants cause you to get worse?  01:59:35 - Seed oils Do you agree that seed oils are some of the worst things you can eat? 02:03:38 - Conception  In the past 4 years I've tried many different things in order to conceive, nothing seems to be working.

There is no such thing as “good” cancer.In this solo episode, Victoria dives into a part of thyroid cancer that rarely gets talked about - what happens after treatment ends.While thyroid cancer often has a good prognosis, many patients are left navigating fatigue, hormone changes, TSH suppression, scan anxiety, and long-term health concerns with little guidance or support. Being told you're “cancer-free” doesn't always mean you feel okay, and this episode is for anyone who's felt dismissed in that space.We talk about:• Why thyroid cancer doesn't end when treatment does• What life can look like after surgery and radioactive iodine• Why fatigue is so common - even when labs look “fine”• TSH suppression: why it's used, and the long-term risks to bones, heart, and nervous system• What exercise and lifestyle choices actually support recovery (and what can backfire)• The emotional weight of survivorship that no one prepares you for• How loved ones can better support someone after thyroid cancerThis episode isn't just about cancer, it's about survivorship, long-term care, and learning how to live in a body that's been changed.Whether you've had thyroid cancer, love someone who has, or have ever been told you should be “fine” when you don't feel fine... this conversation is for you.For more information on Thyroid cancer and thyroid cancer awareness, Vic's instagram is here.For more information & to join the Confident Clinician check it out here! Be sure to DM us on Instagram once you become a member for your special gift! Don't forget to follow us on Instagram @girlsgonewellnesspodcast for updates and more wellness tips. You can also subscribe to our Youtube Channel @Girlsgonewellnesspodcast to watch our episodes! Please subscribe to our podcast and leave a review—we truly appreciate your support. Let's embark on this journey to wellness together!DISCLAIMER: Nothing mentioned in this episode is medical advice and should not be taken as so. If you have any health concerns, please discuss these with your doctor or a licensed healthcare professional.

Eleven years after thyroid cancer, Patrick Sullivan realized he was still furious that no one could explain what happened to his body, so he made a documentary exposing how America's food system went rotten and how everyday people are reviving it.Social Links:•Jigsaw Health on the web: https://www.JigsawHealth.com•Jigsaw Health on TikTok: https://www.tiktok.com/@jigsaw_health•Jigsaw Health on IG: https://www.instagram.com/jigsaw_health/•Jigsaw Health on FB: https://www.facebook.com/JigsawHealth/•Patrick on X: https://twitter.com/realPatrickJr •Patrick on IG: https://www.instagram.com/patricksullivanjr/ •Breaking Big Food on IG: https://www.instagram.com/breakingbigfood/Send Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Stay Off My Operating Table on X: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Stay Off My Operating Table on Amazon Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart Health Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

In this episode of Navigating Cancer TOGETHER, host Talaya Dendy welcomes back award-winning journalist, poet, and two-time cancer survivor Annamaria Scaccia. Annamaria shares her powerful story of surviving both kidney and thyroid cancer by age 40 and how she is transforming her life through bodybuilding and advocacy. They discuss the psychological power of strength training, the challenges of managing rare cancer types, how cancer impacts relationships, and the importance of self-awareness in the healing process. Tune in to discover how physical discipline, raw truth, and giving yourself grace can help you reclaim your power and navigate the complex emotional landscape of long-term survivorship.✨Episode Highlights:00:02:32 Annamaria's Origin Story00:05:39 Transitioning from Kickboxing to Bodybuilding after a Kidney Cancer Diagnosis00:09:18 Bodybuilding for Healing and Trauma Recovery00:17:45 Self-Awareness and the Truth of the Iron00:20:50 Navigating a Second Cancer Diagnosis00:27:41 Addressing Multiple Primary Cancers Transcript: https://bit.ly/podscript178Connect & Engage with Annamaria:Links: https://linktr.ee/gotchascaccia?utm_source=linktree_profile_share<sid=e18723c7-b1a1-4be2-9794-507317879f6cInstagram: https://www.instagram.com/gotchascaccia/LinkedIn: https://www.linkedin.com/in/annamariascaccia/Podcast: https://www.kidneycancer.org/podcast/National Cancer Survivor Month Episode: https://youtu.be/JlET8Ljujiw?si=f1_b4aAJ_rkTopk2Join the Community: Looking for a safe space to share your raw truth? Join the waitlist for the Navigating Cancer TOGETHER Cancer Community Forum. Connect with others in a private, supportive environment completely free from the noise and distractions of social media. Be the first to know when we open: https://www.ontheotherside.life/forum-waitlistSponsor: This episode is brought to you by On the Other Side. Thank you for your support! It helps to bring these critical conversations to life.Hosted, Produced, Written, and Edited by: Talaya DendyDisclaimer: The information on this podcast is for general informational purposes only and SHOULD NOT be used as a substitute for sound professional medical advice, evaluation, or care from your physician or other qualified health care provider.Hosted on Ausha. See ausha.co/privacy-policy for more information.

With updated thyroid cancer guidelines, adjunct diagnostic and treatment tools, and growing interest in minimalist approaches, it is increasingly challenging to know the optimal management for patients with small, differentiated thyroid cancer including when to refrain from operating. In this episode, we discuss the nuanced decision making in managing these patients, the multiple factors that are taken into consideration, and strategies in conducting efficacious conversations with patients. Hear from our world-renowned expert panel, Dr. Michael Tuttle, Professor and Chief of Endocrinology at Memorial Sloan Kettering Cancer Center, and Dr. Douglas Fraker, The Jonathan Rhoads Professor of Surgery Emeritus at the University of Pennsylvania , moderated by Dr. Mahsa Javid, Endowed Chair in Endocrine Surgery.

Drs Kaniksha Desai and Whitney Goldner discuss a new guideline approach for active surveillance for selected patients with low-risk papillary thyroid cancer. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0 Kaniksha Desai, MDAssociate Professor of Medicine, Department of Endocrinology, Stanford School of Medicine, Palo , Whitney S. Goldner, MD, Professor; Head, Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado

In this episode of Major Pain, we continue our talks with people dealing with hidradenitis suppurativa. Today we talk to Angel, a mother of five who has had multiple health challenges. A self described “homestead mom”, Angel loves to grow vegetables in the garden and make her own food like butter whenever she is able. She stays busy homeschooling her autistic son while raising her other four children, including a fifteen month old. She hopes someday to get a small acreage and have a few animals and live the country life. At thirty years old, she was diagnosed with thyroid cancer and had to have multiple surgeries to drain and remove the liquid filled tumor, and eventually her entire thyroid. After the surgeries and radiation treatment, she still struggles with getting the right supplements to replace her thyroid hormones, properly absorb nutrition and avoiding fluctuations in weight. After the birth of her son, the skin symptoms that had been an undiagnosed since she was a teenager became much worse.  She had struggled with doctors telling her that she had contact rashes or allergies to certain fabrics or personal care products like deodorant.  Finally, at thirty three years old she got the diagnosis of hidradenitis suppurativa.  While finally being diagnosed was a relief, it was also the beginning of a long road looking for treatments.  She tried Humera but experienced minimal relief with a lot of side effects.  Cosentyx had worked fairly well for her until she became pregnant with her youngest child.  Now she is attempting to get back on a new medication but has struggled with insurance for approval for a year. On this podcast episode she talks us through her journey so far, and discusses her public advocacy as @hsqueen96. PlayWatch the episode on YouTube or Spotify, listen here on our website or on your favorite podcast platform. PODCAST LINKSWEBSITE: https://majorpainpodcast.comEMAIL: majorpainpodcast@gmail.comPATREON: https://www.patreon.com/majorpainpodcastSUBSCRIBE: https://majorpainpodcast.com/subscribeSPOTIFY: https://open.spotify.com/show/5NDoD07WJmICdfdRKq0TyNAPPLE PODCASTS: https://podcasts.apple.com/us/podcast/major-pain/id1562947550?mt=2&ls=1 SOCIAL MEDIAINSTAGRAM: https://www.instagram.com/majorpainpodcastTIKTOK: https://www.tiktok.com/@majorpainpodcastYOUTUBE: https://www.youtube.com/@MajorPainPodcastFACEBOOK: https://www.facebook.com/majorpainpodcast AFFILIATE LINKSRARE PATIENT VOICE: https://rarepatientvoice.com/MajorPainPodcastAMAZON SHOP: https://www.amazon.com/shop/majorpainpodcastNEURAHEALTH: https://www.neurahealth.co/majorpain

Drs Kaniksha Desai and Mimi Hu discuss RET inhibitors for advanced medullary thyroid cancer on the Thyroid Stimulating Podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0 Kaniksha Desai, MD, Associate Professor of Medicine, Department of Endocrinology, Stanford School of Medicine, Palo Alto, California Mimi I. Hu, MD, Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas

In this episode of The Everyday Ironman Podcast, we sit down with Dana Crews to unpack her powerful journey back to Ironman California. Dana's path to endurance sport is anything but ordinary—she grew up competing in basketball, cross-country, and track before majoring in Theatre in college. After losing her father, she returned to running as a way to raise money for cancer-related charities, only to face her own Thyroid Cancer diagnosis in 2014.With a background in CrossFit, Spartan Racing, and even coaching, Dana brings a unique blend of grit and creativity to triathlon. She completed her first Ironman at IMCA in 2023 and returned this year aboard her custom tie-dye Trek Speed Concept Project One. Dana shares what she loves most about the IMCA course, what she'd improve, and why her Great Danes keep her grounded.Follow Dana on YouTube: @Trihrdrgrl#EverydayIronman #IronmanCalifornia #AgeGroupAthlete #Trihrdrgrl #TriathlonJourneyFit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts SpotifySupport the show

With an animal based diet, Selina lost over 112 pounds, regained fertility, and greatly improved her thyroid related symptoms, leading to reversal of her thyroid cancer diagnosis. Instagram: @primalfoxhealth / @thecarnivorecommunityworldwide YouTube:: @primalfoxhealth Website: https://stan.store/primalfox Timestamps: 00:00 Trailer 00:35 Introduction 05:59 Fitness, strength, and misguided advice 07:19 Postpartum weight gain and fatigue 11:10 Thyroid concerns and treatment options 15:19 Healing journey through keto/animal-based eating 18:27 Thyroid mass and treatment options 23:28 From processed foods to sunlight 25:08 Vegan childhood to eating meat 31:08 Ketogenic pregnancy and barbecue 34:17 Diet transition and perspective 37:40 Realizing hidden pain through diet 40:07 Where to find Selina Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

What happens when a systems engineer is told she has cancer—but refuses to accept that medication and surgery are her only options?   In this inspiring episode of The Exam Room Podcast, host Chuck Carroll sits down with Dr. Ruby Lathon, who healed her thyroid cancer naturally through the power of food. Discover how she turned her research skills into a mission to help others use plants to prevent and reverse disease.   Ruby shares the exact steps she took to restore her health—including how she eliminated dairy, sugar, and processed foods, and the mindset shift that helped her truly heal. Today, she's thriving as a wellness coach, author, and founder of Ruby Reds Vegan, teaching people that food truly is medicine.   What You'll Learn - How Dr. Ruby Lathon reversed thyroid cancer with plant-based nutrition - The foods that help regulate thyroid function and fight inflammation - Ways to make whole-food, plant-based meals delicious and satisfying  

Drs Kaniksha Desai and Julie Ann Sosa discuss the 2025 American Thyroid Association guidelines for the management of differentiated thyroid cancer. This podcast is intended for healthcare professionals only. Kaniksha Desai, MD, Associate Professor of Medicine, Department of Endocrinology, Stanford School of Medicine, Palo Alto, California Julie Ann Sosa, MD, Professor, Department of Medicine, University of California, San Francisco (UCSF) To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0

In this episode of Accelerated Health with Sara Banta, I talk about a recent study that reveals a concerning connection between X-ray machines and thyroid cancer. I discuss how routine medical imaging—like dental or chest X-rays—might be contributing to the alarming rise in thyroid cancer cases, and what you can do to protect yourself.If you've ever had an X-ray—or have concerns about thyroid issues—this is a must-watch episode. I break down the latest research in an easy-to-understand way, so you can make informed decisions about your health.Supplements Featured In This Episode:• Accelerated Radiation and Heavy Metal Detox Kit https://www.acceleratedhealthproducts.com/products/heavy-metal-detox-kit • Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Cellular Detox® Powder https://www.acceleratedhealthproducts.com/products/accelerated-cellular-detox-powder • Accelerated Liver Care™ https://www.acceleratedhealthproducts.com/products/accelerated-liver-care Not sure what food to eat and avoid? This guide is for you.⬇️

What happens when cancer treatment becomes the greatest catalyst for sovereignty?In this episode, I speak with Jocelyn, a Tennessee mother who walked away from conventional medicine after surviving thyroid cancer and having her thyroid removed at 25 years old.That experience changed everything. Jocelyn made a vow: never again would she hand her body over to the system. She carried that fierce sovereignty into motherhood, choosing to walk the sovereign path in her pregnancy and birth.She speaks to the comfort of finding the perfect sovereign birth witness and how being around animal birth her whole life helped her understand what she needed to do.Inside this episode:How surviving thyroid cancer led Jocelyn to question everything she'd been taughtThe moment in the hospital that made her vow never to surrender her body againWhat a wild pregnancy looked like day-to-day, with no tests, scans, or appointmentsWhat it takes to hold the line with family and community when your choices challenge the normTimestamps:[00:00] Introduction[03:23] Facing thyroid cancer and the trauma of a life-threatening hospital experience[11:25] Regrets about rushed surgery instead of looking into alternative treatments[29:41] Disappointment with midwives leading to the discovery of freebirth[37:52] Finding trust and support through The Lighthouse and connecting with a birth keeper[41:03] Jocelyn's freebirth storyResources Mentioned:Veda Revival | WebsiteThe Complete Guide to Freebirth | CourseThe Lighthouse | WebsiteFind more from Emilee on Instagram, YouTube and the Free Birth Society website.Disclaimer: Free Birth Society, LLC of North Carolina shares personal and educational stories and experiences related to freebirth and holistic care. This content is not medical advice, and we are not a licensed midwifery practice. Testimonials reflect individual experiences; results may vary. For services or scheduling, contact info@freebirthsociety.com. See full disclaimer at freebirthsociety.com/youtubeterms.

Stuck in a cycle of bloating, fatigue, and stubborn weight? In this multi-part series I break down the confusing world of hypothyroid nutrition, fitness, and lifestyle. I'm cutting through the noise answering all your thyroid questions and giving simple, actionable tips to help you stop spinning. Show notes Check out The Club - My membership for symptom-free living with hypothyroidism Book a consultation!  Grab your FREE hypothyroid weight loss guide! 

What are your thoughts on the perfect amino?  I want to support my strength training, aerobics, yoga and pilatesWhen I take protein powders and creatine, urination comes to a halt for several hours.  Is this normal?Are drip coffee makers made from plastic bad for your health?I have a 50% chance of thyroid cancer based on molecular testing.  Must I have it removed?I'm taking 10 mg. DHEA, based on my practitioner's recommendation 10 years ago. Is it safe to continue?Do you recommend ivermectin or fenbendazole?

ANH fighting for free speech on the true benefits of supplementsWhat can I do about Morton's Neuroma aside from surgery?Which form of magnesium do you recommend for mitral valve prolapse with regurgitation?

 Hashimoto's, Hormones, Neck Checks & the Future of Thyroid Screening Thyroid cancer is on the rise among midlife women—and most don't even know they're at risk. In this eye-opening episode of Asking for a Friend, Dr. Rashmi Roy, Director of Thyroid Surgical Services at the Clayman Thyroid Center and one of the world's most experienced thyroid surgeons, explains why traditional blood work often misses thyroid cancer completely—and what women can do about it.You'll learn: ✅ Why thyroid cancer rarely shows symptoms and often doesn't appear on routine thyroid labs ✅ The difference between thyroid disease (hypothyroidism, Hashimoto's) and thyroid cancer ✅ The life-saving power of a simple 2-minute self-neck check you can do today ✅ How Dr. Roy's groundbreaking mobile screening program is catching cancers at a higher rate than mammograms and pap smears ✅ Why she's advocating for thyroid ultrasounds to become routine preventive care for women over 30Dr. Roy also shares patient success stories, her journey into thyroid surgery, and practical steps you can take now to protect your thyroid health. Plus, discover her educational YouTube channel, Goiter Guru, where she empowers women with knowledge about thyroid disease and surgery.

Papillary thyroid cancer is the most common type of thyroid cancer, and yet in rare cases, this cancer may originate in locations other than the thyroid glands. In this episode, host Aaron Lohr talks about causes, prevalence, and treatment for papillary thyroid cancer and the rare phenomenon known as ectopic papillary thyroid cancer with Nikita Dhir, MD, of University of Texas Health Science Center at Houston. Dr. Dhir and colleagues presented research at ENDO 2025 in San Francisco titled, “Where Is the Primary Papillary Thyroid Cancer?” Show notes are available at https://www.endocrine.org/podcast/enp101 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Nutritionist Leyla Muedin reveals the alarming increase in obesity-associated cancers in the United States over the past two decades. Highlighting findings from a recent study presented at the Endocrine Society's annual meeting, Leyla underscores the significant rise in cancer deaths linked to obesity, particularly among women, older adults, Native Americans, and Black Americans. She also explores the complex causes of obesity, including genetics, lifestyle, and environmental factors, and offers insights into effective weight management strategies. Additionally, Leyla examines the high rates of heart disease in various U.S. states, emphasizing the importance of lifestyle modifications and public health initiatives to combat cardiovascular diseases.

In this episode of SurgOnc Today, Dr. Yinin Hu from the University of Maryland and Dr. Jennifer Kuo from the Columbia University Medical Center discuss current evidence, best practices, and future directions for percutaneous ablative therapy for thyroid cancer.

Think your thyroid surgery was the end of the road? Think again. The root causes are still active—and if left unaddressed, they could trigger new problems. Listen to this episode to learn what your doctor didn't tell you. Join my FREE Hypothyroid Heroes Q&A Coaching Call! Show notes Check out The Club - My membership for symptom-free living with hypothyroidism Book a consultation!  Grab your FREE hypothyroid weight loss guide! 

Thyroid Cancer: Hygienist Survives Surgery and Recommends Dental Monitoring for SymptomsBy Debbi Viger, RDH, BHSOriginal article published on Today's RDH: https://www.todaysrdh.com/thyroid-cancer-hygienist-survives-surgery-and-recommends-dental-monitoring-for-symptoms/Need CE? Start earning CE credits today at ⁠⁠⁠⁠⁠⁠⁠https://rdh.tv/ce⁠⁠⁠⁠⁠⁠⁠Get daily dental hygiene articles at ⁠⁠⁠⁠⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠⁠⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠⁠⁠⁠⁠Follow Kara RDH on Facebook: ⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠⁠⁠⁠⁠Follow Kara RDH on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/kara_rdh/

Send us a textYour body is complex—your hormones, your digestion, your emotions, your energy. And yet somehow, we expect to know exactly how to “fix” it the moment something feels off. In this episode, I'm talking about what it really means to become a lifelong learner of your own body.From ignoring signs like food intolerances to pushing through extreme workouts and wondering why we're constantly exhausted or in pain, I've been there. I share stories about my own missteps—like ignoring lactose intolerance, trying to go from zero to 24 miles in a day, or letting someone else's pace dictate my own.But the truth is, progress doesn't happen in a single day—it happens in every small, consistent choice we make. This is your reminder to slow down, pay attention, and give your body the grace and love it deserves. You don't need to be a badass for one day. You need to be consistent for life.

Are you up to date with management of patients with NTRK fusion-positive thyroid cancer? Credit available for this activity expires: 7/14/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002660?ecd=bdc_podcast_libsyn_mscpedu

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠Thyroid Cancer ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Send us a text This episode reclaims “vanity” as a legitimate motivator for change. It's okay to want to feel sexy, rock a bikini, turn heads, or look good in your vacation photos. Not every goal has to be about trauma healing or inner peace—sometimes you just want to strut, and that's enough to get you started. 

Send us a textIn this episode, I talk about the subtle ways we give up control—at work, in our families, and in the quiet rebellion that shows up when we abandon the habits we say we care about.I unpack:The subconscious resistance we create when we feel boxed inHow “taking weekends off” is costing us 35% of our progressThe tension between personal responsibility and burnoutWhy intentional mornings can change your entire weekIf you've ever wondered why you're stuck—or why you feel like you're always starting over—this one's for you. 

Aly Arenholz was a freshman in high school when she was diagnosed with Stage 2 Thyroid Cancer when she was 15 years old in 2021. After undergoing a very difficult battle during much of it, Aly just graduated from high school and will be attending the University of Kansas in the fall where she hopes her career path will focus on becoming a Child Life Specialist. Aly will also talk about her Non-Profit KICK CANCER LIKE A GIRL BOSS, which she started while in treatment and focuses on trying to bring a smile to the faces of Pediatric Cancer Patients. 

Send us a textHow did last week go? What is the plan this week? These questions are answered, along with a discussion of your community and how to build it up. Do not forget to join the free Facebook page for Larger Than Life Coaching. Living Larger Than Life. 

Send us a textThis episode looks back on the last week and how I did getting back on track. We discuss our goals and how they can be adapted to suit our current situation, while also considering how they should align with our desired outcome.

Death isn’t an easy thing to talk about, but Genevieve Keeney-Vazquez has made it her life work. Funeral Director and CEO of the National Museum of Funeral History, she shares what happens when someone dies and how important the right type of service can be to loved ones. During her service to our country, she’s handled fallen soldiers, caring for them in ways that will touch your heart.During this episode, you’ll learn about her early obsession with death and how it shaped her life, and how her sister’s breast cancer journey inspired her to take initiative in being her own advocate. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Subscribe to The Final Curtain Never Closes on Apple, Spotify, or wherever you get your podcasts. Learn more about The National Museum of Funeral History HERE. Key Questions Answered 1. How did breast cancer first impact Genevieve Keeney-Vazquez’s family? 2. Can young women get breast cancer, and how often are their concerns dismissed? 3. How did Genevieve’s sister respond after finally being diagnosed with breast cancer? 4. Was there a genetic or hormonal factor linked to the cancers in Genevieve’s family? 5. What other cancer experiences did Genevieve’s family face? 6. How did Genevieve advocate for her own breast health given her family history? 7. What was Genevieve’s experience as a female veteran seeking breast screening? 8. How did Genevieve’s professional work with death and end-of-life care connect to her family’s experiences 9. Are families ever truly prepared for death, even those with professional experience? 10. What is the significance of funerals and memorials for those left behind? Timestamped Overview 00:00 Too Young for Breast Cancer? 05:01 Battling Breast and Thyroid Cancer 08:45 Proactive Health Measures for Veterans 12:01 Evolving Women's Clinic at VA 14:44 Curiosity About Death's Visibility 17:02 Misconceptions of Funeral Directors 20:40 Emotional Reunion Moment 25:06 Foresight and Hope Amidst Loss 26:20 Reflections on Death and Fear 29:53 Purpose and Importance of Funerals 34:12 Exhibit Reconnects Siblings Through ArtSee omnystudio.com/listener for privacy information.

She endured a total thyroidectomy and survived the exhausting struggle of hyperthyroidism —then finally uncovered the secret that transformed her health. What was it?Sandy Kruse reveals how having thyroid cancer turned her life upside down, only to lead her to be her own health advocate. She talks about the difficult recovery, and the moment she realized that truly listening to her body was the key to healing. From experimenting with medications to refining her nutrition, Sandy's experience offers powerful lessons on navigating thyroid health. Tune in to hear how she turned every challenge into a stepping stone for her wellness and completely!Episode Timeline: 0:00 - Episode Overview1:18 - Podcast Intro 1:51 - Meet Sandy Kruse 3:00 - It all began after her second childbirth4:11 - Signs pointed to postpartum thyroiditis but went undiagnosed4:44 - Her daughter's cancer was followed by her own diagnosis6:05 - A sudden migraine revealed a hidden cancer7:53 - Doctors found five thyroid nodules and one was malignant8:44 - Full thyroid removal was recommended due to bilateral nodules9:17 - Exploring new options like radiofrequency ablation10:07 - Why choosing the right thyroid surgeon matters13:04 - Hypothyroidism stole her energy and sense of self14:35 - Learning how hormones and stress impacted her healing17:21 - Suppressed TSH triggered hyperthyroid symptoms for years18:44 - Hyperthyroid state and bone loss risks in perimenopause19:10 - Her wellness journey began after lowering thyroid meds20:46 - Severe symptoms and slow healing on T4-only meds21:16 - Addicted to acid blockers after rushed diagnosis22:22 - Developed Barrett's esophagus after trying to quit meds23:49 - How she managed digestion and iron levels through supplements25:56 - Estrogen dominance and low ferritin in her 40s26:44 - Confusion around weight gain and experimenting with diet28:17 - Developed insulin resistance while intermittent fasting29:02 - Stopped fasting and started listening to her body31:57 - Protein needs vary by lifestyle and body type32:53 - Protein requirements depend on activity and goals34:21 - Switched to collagen for joint pain relief in menopaus36:08 - Chose natural sugars over erythritol and monk fruit42:46 - Recommends fermented foods and human strain probiotics44:15 - Menopause and thyroid issues talk recommendation46:27 - Where to Connect with Sandy Kruse48:30 - Final Thanks and Episode Wrap-Up48:40 - Podcast Outro49:01 - Episode Conclusion and final takeaways About Sandy KruseSandy Kruse is a passionate advocate for alternative wellness and healing methods. A podcast host, Holistic Health Practitioner, biohacker, and aging-well enthusiast at 52, Sandy began her new career three years ago. With a Bachelor's in English Literature and a diploma in holistic nutrition from the Canadian School of Natural Nutrition, she develops healthier recipes and works one-on-one with women over 40 to uncover the root causes of their symptoms. After her thyroidectomy, she discovers how balance in body, mind, and soul is essential for living a happy, healthy life well into the golden years.Connect with Sandy Kruse Sandy Kruse's Website Do You Want Help Saving Your Thyroid? Access hundreds of free articles at www.NaturalEndocrineSolutions.com Visit Dr. Eric's YouTube channel at www.youtube.com/c/NaturalThyroidDoctor/ To work with Dr. Eric, visit https://savemythyroid.com/work-with-dr-eric/

Management and Ongoing Monitoring of Thyroid Neoplasms Join us as we dive deep into the approach for thyroid nodules with our two fantastic guests, Dr. Kaniksha Desai (Stanford Medicine) and Dr. Ana Chindris (Mayo Clinic)! Learn how to stratify these nodules for cancer risk and walk alongside our patients during treatment for thyroid cancer.  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro, guest bios Case From Kashlak Thyroid nodule evaluation and management Thyroid cancer diagnosis and treatment GLP-1s relationship to thyroid nodules and cancer Outro Credits Writer, producer, show notes, infographic, cover art: Alise Burke, MD  Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest:  Kaniksha Desai MD and Ana Chindris MD Sponsor: Panacea Let Panacea Legal help you today at Panacea.Legal Sponsor: Grammarly Download Grammarly for FREE at grammarly.com/PODCAST Sponsor: Babbel Babbel is gifting our listeners 60% off subscriptions at Babbel.com/CURB. 

In this enlightening episode of Passion Struck, Johann Hari, acclaimed author of "Magic Pill," takes us on a deep dive into the extraordinary benefits and hidden risks of new weight loss drugs. Johann explores obesity not just as a personal struggle but as a profound societal issue intricately linked to our shift from whole foods to processed foods.These revolutionary drugs enhance satiety hormones, significantly aiding weight loss and reducing the risk of heart conditions. However, Johann also sheds light on the potential risks, including thyroid cancer and pancreatitis, and the complex impact these drugs can have on mental health by revealing underlying emotional eating patterns.Order a copy of my book, "Passion Struck: Twelve Powerful Principles to Unlock Your Purpose and Ignite Your Most Intentional Life," today!  Recognized as a 2024 must-read by the Next Big Idea Club, the book has won the Business Minds Best Book Award, the Eric Hoffer Award, the International Book Awards for Best Non-Fiction, the 2024 Melanie P. Smith Reader's Choice Contest by Connections eMagazine, and the Non-Fiction Book Awards Gold Medal. Don't miss the opportunity to transform your life with these powerful principles!Full show notes and resources can be found here:  https://passionstruck.com/johann-hari-truth-they-dont-tell-about-ozempic/In this episode, you will learn:The rise of obesity is linked to the transition from fresh, whole foods to processed or ultra-processed foodsNew weight loss drugs work by injecting an artificial copy of the hormone GLP-1, which helps regulate appetiteObesity is a significant risk factor for various health conditions, including heart disease, diabetes, and cancerWeight loss drugs like Ozempic can reduce the risk of heart attacks and strokes by 20%Potential risks of weight loss drugs include an increased risk of thyroid cancer and pancreatitisWeight loss drugs can disrupt eating patterns and bring underlying emotional drivers of eating to the surfaceAll things Johann Hari: https://johannhari.com/SponsorsBrought to you by Clariton, fast and powerful relief is just a quick trip away. Ask for Claritin-D at your local pharmacy counter. You don't even need a prescription! Go to “CLARITIN DOT COM” right now for a discount so you can Live Claritin Clear.--► For information about advertisers and promo codes, go to:https://passionstruck.com/deals/Catch More of Passion StruckWatch my solo episode on The 6 Key Steps to Bold Risk-Taking for Personal Growth.Can't miss my episode withMorley Robbins on How You Reclaim Your Health and VitalityListen to my interview withDr. Will Cole on how to restore your gut-feelings connectionCatch my interview with Dr. Kara Fitzgerald on How to Become a Younger You by Reversing Your Biological AgeListen to Seth Godin on Why We Need Systems Change to Save the PlanetLike this show? Please leave us a review here-- even one sentence helps! Consider including your Twitter or Instagram handle so we can thank you personally!